Abstract: Novel human tissue-type plasminogen activator variant that a) retains substantially full biological activity b) has a modified carbohydrate structure and c) has an altered in vivo half-life. Means for preparation of the variants and results of assays measuring function of the activators are also disclosed.

Abstract: A method and pharmaceutical composition for the prevention of fibrin deposition or adhesion formation by topical application of a composition to a site of potential fibrin deposition or adhesion formation comprising a sparingly soluble enzyme that is continuously released at that site for a period of time of from about three days to two weeks which may include an inert adherence enhancing vehicle.

Abstract: Human tissue plasminogen activator (t-PA) is produced in useful quantities using recombinant DNA techniques. The invention disclosed thus enables the production of t-PA free of contaminants with which it is ordinarily associated in its native cellular environment. Methods, expression vehicles and various host cells useful in its production are also disclosed.

Abstract: Disclosed is a complete description of the preparation of novel, recombinant human immune interferon and des-CYS-TYR-CYS recombinant human immune interferon via recombinant DNA techniques utilizing any of an assortment of expression vectors and host cultures. The human immune (gamma) interferon (IFN-.gamma.), is isolated and characterized in terms of DNA and amino acid sequences, physical attributes and biological activity.

Abstract: The present invention describes modified baculoviruses possessing unique restriction endonuclease cleavage sites downstream of the promoter of the baculovirus viral inclusion, polyhedron and/or protein P10 genes and a method for obtaining such modified baculoviruses. Such modified baculoviruses are useful for the direct cloning of heterologous DNA into the unique endonuclease restriction sites and the consequent expression of the heterologous DNA inserted therein.

Abstract: Antigenized antibodies which have inserted within their third complementarity determining regions, antigenic epitopes not found in immunoglobulins are described.

Abstract: Minority carrier bulk lifetime maps are accomplished using in-situ .mu.-PCD measurement techniques on a non-oxidized Si specimen of either polarity. Surface passivation of the specimen is accomplished chemically, preferably using a solution of iodine in ethanol with a concentration in the range of about 0.02 mol.multidot.dm.sup.-3 to about 0.2 mol.multidot.dm.sup.-3. For n-type specimens, a solution of concentrated alkaline such as ammonia, sodium- and potassium-hydroxide is especially effective. For either type specimens, a solution of HF at about 40% m/m is also effective. Surface passivation according to the present invention reduces surface recombination velocities to 10 cm/second or less. The specimen to be measured is placed in a container of passivation solution such that the specimen surfaces are covered with a solution film of about 1 mm or less. The container preferably is transparent to microwave and laser optical energy, and passivation and measurement can occur simultaneously.

Abstract: A pharmaceutical composition comprising dermatan sulphate, together with a low molecular weight heparin, free or fixed combination, is useful as a antithrombolytic agent with a low risk of bleeding complications.

Abstract: Geographical positional data is obtained for an underground object by locating the object using a device that locates underground objects. An apparatus that receives data from a global position system ("GPS") provides data identifying global position of the device, and thus also of the located underground object. A data storage unit stores such positional data, which may be used in the future to re-locate the underground object. The GPS-data receiving apparatus can preferably receive data from at least one overhead GPS satellite and from a secondary stationary receiver. Data from the secondary stationary receiver may be modulated on to a signal transmitted along a detected underground cable object.

Abstract: The present invention relates to novel, stable recombinant gamma interferons exhibiting in greater or less degree the antiviral and antiproliferative activity in humans and pH 2 labile properties characteristic of native human gamma interferon. The amino acid sequence of such an interferon comprises, from the N terminus: ##STR1## wherein X is a methionine residue or hydrogen and Y is a glutamine residue or, where X is hydrogen, Y is either a glutamine or a pyroglutamate residue.

Abstract: The present invention provides compounds that function as hydrolytic enzyme inhibitors (inactivators) and substrates. These compounds are useful in assays to detect and measure levels of hydrolytic enzyme activity and are more particularly useful in treatment regimens for various disease states and conditions implicating the underlying specific hydrolytic enzyme. Examples of hydrolytic enzymes include, but are not limited to, phospholipases, lipases, esterases, proteases, etc.

Abstract: This disclosure relates to the identification of a new voltage-gated potassium channel gene, Kv1.7, which is expressed in pancreatic .beta.-cells. The invention utilizes this new potassium channel for assays designed to identify extrinsic materials with the ability to modulate said channel for the development of therapeutics effective in the treatment of non-insulin-dependent diabetes mellitus.

Abstract: 1,3,5-Triazine-2,4,6-tris-alkylaminocarboxylic acid amino esters of the general formula (I): 1,3,5-triazine-2,4,6-tris[NH--(CH.sub.2).sub.n --CO--O--R.sup.1 ], in which R.sup.1 denotes the radical of an alkanolamine, can be employed as biocidal or biostatic compounds in aqueous systems, in particular in cooling lubricants.

Abstract: Oligonucleotide-polyamide conjugates of the formula X--L--Y, where X is a polyamide, Y is an oligonucleotide, and L is a linker which forms a covalent bond with the amino-terminus of the polyamide X and the 3' phosphate group of the oligonucleotide Y. Conjugates may be synthesized by assembling a polyamide on a solid support matrix, adding a suitable linker molecule, followed by synthesis of the oligonucleotide. Methods for detecting specific polynucleotides with oligonucleotide-polyamide conjugates are also described.

Abstract: Concentrated phosphorus fertilizers are disclosed that comprise a buffered composition of an organic acid and salts thereof and a phosphorous-containing acid and salts thereof. The concentrated phosphorus fertilizers can be diluted with water of pH ranging from about 6.5 to about 8.5 at ratios of concentrate to water at about 1:40 to about 1:600 to result in a fertilizer having a pH in the range acceptable for foliar uptake of phosphorus.

Abstract: Antibodies have been recombinantly produced which contain the NANP tetrapeptide of Plasmodium Falciparum within their third complementarity determining region in N-terminus of the variable region. These antibodies are capable of eliciting an antibody response.

Abstract: This disclosure relates to two separate and distinct inward rectifier K.sup.+ channel expression products and the the genes which encode each expression product. The IRK1 gene (SEQ. ID NO: 1) encodes an inward rectifier K.sup.+ channel and the GIRK1 gene (SEQ. ID NO: 31) encodes a G protein coupled muscarinic K.sup.+ channel. The disclosure relates to the uses of these expression products, particularly in combination with identifying physiological processes mediated by these channels, such as regulation of heartbeat and insulin release and materials modulating or blocking same.

Abstract: A non-radioactive, spectrophotometric, microtiter plate assay for human cystolic phospholipase A.sub.2 (cPLA.sub.2) is described. The assay utilizes a novel synthetic thiol-phospholipid analog as a substrate. In one embodiment, the substrate is a phosphatidylcholine derivative with an arachidonoylthioester in the sn-2 position and an alkenyl-ether or alkenyl-ether in the sn-1 position. The alkyl-ether and the alkenyl-ether in the sn-1 position of the substrate ensures that the assay will only measure cPLA.sub.2 activity and will not be complicated by metabolism of the lysophospholipid product by the enzyme's and lysophospholypase activity.

Abstract: A composite device which may be implanted in the cornea of the human eye to replace damaged or diseased portions, and a method of manufacturing the said device, are disclosed. The device consists of a transparent central portion intimately attached to an opaque spongy rim. Both portions are made of hydrogel materials produced in different conditions of polymerization during a two-stage process performed in a specific moulding unit. The spongy rim promotes and maintains cellular invasion from the host corneal tissue, thus providing a tight union between implant and recipient cornea which prevents the postoperative extrusion of the implant.